You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAtenolol
Accession NumberDB00335  (APRD00172)
TypeSmall Molecule
GroupsApproved
DescriptionA cardioselective beta-adrenergic blocker possessing properties and potency similar to propranolol, but without a negative inotropic effect. [PubChem]
Structure
Thumb
Synonyms
1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol
2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
Atenololum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act AtenololTablet50 mgOralActavis Pharma Company2004-08-13Not applicableCanada
Act AtenololTablet100 mgOralActavis Pharma Company2004-08-13Not applicableCanada
Ag-atenololTablet50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-atenololTablet100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-atenololTablet25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
AtenololTablet100 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AtenololTablet25 mgOralPro Doc Limitee2009-06-15Not applicableCanada
AtenololTablet100 mgOralSivem Pharmaceuticals Ulc1999-03-09Not applicableCanada
AtenololTablet25 mgOralSivem Pharmaceuticals Ulc2003-04-21Not applicableCanada
AtenololTablet25 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AtenololTablet100 mgOralPro Doc Limitee1989-12-31Not applicableCanada
AtenololTablet50 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
AtenololTablet50 mgOralMeliapharm Inc2011-04-082014-06-25Canada
AtenololTablet50 mgOralPro Doc Limitee1989-12-31Not applicableCanada
AtenololTablet50 mgOralSivem Pharmaceuticals Ulc1999-09-03Not applicableCanada
AtenololTablet100 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Atenolol - Tab 100mgTablet100 mgOralSchein Pharmaceutical Canada Inc.1996-09-052005-07-27Canada
Atenolol - Tab 50mgTablet50 mgOralSchein Pharmaceutical Canada Inc.1996-09-052005-07-27Canada
Atenolol Tablets 100mgTablet100 mgOralPrempharm Inc1996-12-302005-08-05Canada
Atenolol Tablets 50mgTablet50 mgOralPrempharm Inc1996-12-302005-08-05Canada
Atenolol Tablets, BPTablet50 mgOralFc Pharma Inc.1999-06-152000-11-15Canada
Atenolol Tablets, BPTablet100 mgOralFc Pharma Inc.1999-06-152000-11-15Canada
Ava-atenololTablet25 mgOralAvanstra Inc2011-09-152014-08-21Canada
Bci AtenololTablet100 mgOralBaker Cummins Inc2005-07-042009-09-21Canada
Bci AtenololTablet50 mgOralBaker Cummins Inc2005-07-042009-09-22Canada
Bio-atenololTablet100 mgOralBiomed Pharma2013-03-26Not applicableCanada
Bio-atenololTablet25 mgOralBiomed Pharma2013-03-26Not applicableCanada
Bio-atenololTablet50 mgOralBiomed Pharma2013-03-26Not applicableCanada
Dom-atenolol - 100mgTablet100 mgOralDominion Pharmacal1996-10-17Not applicableCanada
Dom-atenolol - 50mgTablet50 mgOralDominion Pharmacal1996-10-17Not applicableCanada
Ftp-atenololTablet100 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-atenololTablet50 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ipg-atenololTablet25 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-atenololTablet50 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-atenololTablet100 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-atenololTablet25 mgOralJamp Pharma Corporation2011-06-09Not applicableCanada
Jamp-atenololTablet50 mgOralJamp Pharma Corporation2011-06-09Not applicableCanada
Jamp-atenololTablet100 mgOralJamp Pharma Corporation2011-06-09Not applicableCanada
Mar-atenololTablet50 mgOralMarcan Pharmaceuticals Inc2012-10-22Not applicableCanada
Mar-atenololTablet100 mgOralMarcan Pharmaceuticals Inc2012-10-22Not applicableCanada
Mar-atenololTablet25 mgOralMarcan Pharmaceuticals Inc2012-10-22Not applicableCanada
Med Atenolol - Tab 100mgTablet100 mgOralMedican Pharma Incorporated1996-07-302011-03-29Canada
Med Atenolol - Tab 50mgTablet50 mgOralMedican Pharma Incorporated1996-07-302011-03-29Canada
Mint-atenolTablet25 mgOralMint Pharmaceuticals Inc2011-06-13Not applicableCanada
Mint-atenolTablet50 mgOralMint Pharmaceuticals Inc2011-06-13Not applicableCanada
Mint-atenolTablet100 mgOralMint Pharmaceuticals Inc2011-06-13Not applicableCanada
Mylan-atenololTablet50 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-atenololTablet100 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-atenololTablet25 mgOralMylan Pharmaceuticals Ulc2007-12-13Not applicableCanada
Ntp-atenolTablet50 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-atenolTablet100 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-atenolTablet25 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-atenol Tab 100mgTablet100 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-atenol Tab 50mgTablet50 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Orb-atenololTablet50 mgOralOrbus Pharma IncNot applicableNot applicableCanada
Orb-atenololTablet100 mgOralOrbus Pharma IncNot applicableNot applicableCanada
Penta-atenolol - 100mgTablet100 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-atenolol - 50mgTablet50 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PMS-atenololTablet25 mgOralPharmascience Inc2002-11-28Not applicableCanada
PMS-atenololTablet50 mgOralPharmascience Inc1998-03-31Not applicableCanada
PMS-atenololTablet100 mgOralPharmascience Inc1998-03-31Not applicableCanada
Ran-atenololTablet50 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-05Not applicableCanada
Ran-atenololTablet100 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-05Not applicableCanada
Ran-atenololTablet25 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-01-18Not applicableCanada
Ratio-atenololTablet100 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Ratio-atenololTablet50 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Riva-atenololTablet25 mgOralLaboratoire Riva Inc2006-07-12Not applicableCanada
Riva-atenolol 100 mgTablet100 mgOralLaboratoire Riva Inc2000-05-23Not applicableCanada
Riva-atenolol 50 mgTablet50 mgOralLaboratoire Riva Inc2000-05-23Not applicableCanada
Sandoz AtenololTablet100 mgOralSandoz Canada Incorporated2000-06-07Not applicableCanada
Sandoz AtenololTablet50 mgOralSandoz Canada Incorporated2000-06-07Not applicableCanada
Septa-atenololTablet25 mgOralSepta Pharmaceuticals Inc2011-07-07Not applicableCanada
Septa-atenololTablet50 mgOralSepta Pharmaceuticals Inc2011-07-07Not applicableCanada
Septa-atenololTablet100 mgOralSepta Pharmaceuticals Inc2011-07-07Not applicableCanada
Taro-atenolol Tab 100mgTablet100 mgOralTaro Pharmaceuticals Inc1993-12-311998-10-21Canada
Taro-atenolol Tab 50mgTablet50 mgOralTaro Pharmaceuticals Inc1993-12-311998-10-21Canada
TenorminTablet100 mg/1OralAstra Zeneca Pharmaceuticals Lp1990-09-01Not applicableUs
TenorminTablet50 mg/1OralALMATICA PHARMA INC.2015-04-15Not applicableUs
TenorminTablet50 mg/1OralAstra Zeneca Pharmaceuticals Lp1990-09-01Not applicableUs
TenorminTablet100 mg/1OralALMATICA PHARMA INC.2015-04-15Not applicableUs
TenorminTablet25 mg/1OralAstra Zeneca Pharmaceuticals Lp1991-02-01Not applicableUs
TenorminTablet25 mg/1OralALMATICA PHARMA INC.2015-04-15Not applicableUs
Tenormin 100mgTablet100 mgOralAstrazeneca Canada Inc1994-12-31Not applicableCanada
Tenormin 50mgTablet50 mgOralAstrazeneca Canada Inc1995-12-31Not applicableCanada
Teva-atenololTablet100 mgOralTeva Canada Limited1991-12-312015-07-24Canada
Teva-atenololTablet25 mgOralTeva Canada Limited2005-11-17Not applicableCanada
Teva-atenololTablet50 mgOralTeva Canada Limited1991-12-312015-07-24Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atenol Tab 100mgTablet100 mgOralApotex Inc1988-12-31Not applicableCanada
Apo-atenol Tab 50mgTablet50 mgOralApotex Inc1988-12-31Not applicableCanada
AtenololTablet25 mg/1OralUnit Dose Services2010-06-10Not applicableUs
AtenololTablet25 mg/1OralClinical Solutions Wholesale2007-12-04Not applicableUs
AtenololTablet100 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-02-20Not applicableUs
AtenololTablet25 mg/1OralSTAT Rx USA LLC2007-12-04Not applicableUs
AtenololTablet50 mg/1OralUnit Dose Services1995-02-22Not applicableUs
AtenololTablet100 mg/1OralMutual Pharmaceutical Company, Inc.1993-03-30Not applicableUs
AtenololTablet100 mg/1OralCardinal Health2011-06-20Not applicableUs
AtenololTablet25 mg/1OralDIRECT RX2015-01-01Not applicableUs
AtenololTablet50 mg/1OralSandoz Inc1991-09-17Not applicableUs
AtenololTablet50 mg/1OralCadila Healthcare Limited2005-08-10Not applicableUs
AtenololTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.1992-05-01Not applicableUs
AtenololTablet25 mg/1OralAphena Pharma Solutions Tennessee, Llc1992-05-01Not applicableUs
AtenololTablet50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-30Not applicableUs
AtenololTablet50 mg/1OralContract Pharmacy Services Pa2010-04-07Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2011-08-102016-11-05Us
AtenololTablet100 mg/1OralPreferred Pharmaceutials Inc.2015-08-20Not applicableUs
AtenololTablet25 mg/1OralTeva Pharmaceuticals USA Inc2004-11-16Not applicableUs
AtenololTablet50 mg/1OralZydus Pharmaceuticals (USA) Inc.2005-10-08Not applicableUs
AtenololTablet50 mg/1OralBlenheim Pharmacal, Inc.2014-01-06Not applicableUs
AtenololTablet25 mg/1OralNu Care Pharmaceuticals, Inc.1992-05-01Not applicableUs
AtenololTablet50 mg/1OralNorthwind Pharmaceuticals, LLC2015-03-26Not applicableUs
AtenololTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.1991-09-17Not applicableUs
AtenololTablet25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet50 mg/1OralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
AtenololTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-02-18Not applicableUs
AtenololTablet50 mg/1Oralbryant ranch prepack2007-12-04Not applicableUs
AtenololTablet25 mg/1OralREMEDYREPACK INC.2015-04-02Not applicableUs
AtenololTablet100 mg/1OralRebel Distributors Corp.1991-12-27Not applicableUs
AtenololTablet100 mg/1OralUnit Dose Services1991-09-17Not applicableUs
AtenololTablet100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.2007-12-04Not applicableUs
AtenololTablet50 mg/1OralProficient Rx LP1991-09-17Not applicableUs
AtenololTablet50 mg/1OralBlenheim Pharmacal, Inc.2010-10-21Not applicableUs
AtenololTablet100 mg/1OralAurobindo Pharma Limited2007-10-31Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2011-03-162016-10-13Us
AtenololTablet50 mg/mgOralLegacy Pharmaceutical Packaging2005-10-08Not applicableUs
AtenololTablet25 mg/1OralMed Health Pharma, LLC2011-01-20Not applicableUs
AtenololTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-09Not applicableUs
AtenololTablet100 mg/1OralMylan Institutional Inc.1997-07-23Not applicableUs
AtenololTablet50 mg/1OralApotheca Inc.2007-12-04Not applicableUs
AtenololTablet25 mg/1OralPack Pharmaceuticals LLC2010-06-10Not applicableUs
AtenololTablet50 mg/1OralPreferred Pharmaceuticals Inc.2016-08-17Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2013-05-22Not applicableUs
AtenololTablet50 mg/1OralPhysicians Total Care, Inc.1995-04-24Not applicableUs
AtenololTablet25 mg/1OralSt Marys Medical Park Pharmacy2007-12-04Not applicableUs
AtenololTablet50 mg/1OralSandoz Inc1991-09-17Not applicableUs
AtenololTablet50 mg/1OralReady Meds1991-09-17Not applicableUs
AtenololTablet25 mg/1OralAv Kare, Inc.2013-06-17Not applicableUs
AtenololTablet100 mg/1OralRed Pharm Drug Inc.2007-12-04Not applicableUs
AtenololTablet100 mg/1OralLake Erie Medical DBA Quality Care Products LLC1991-09-17Not applicableUs
AtenololTablet25 mg/1OralNorthstar Rx LLC2009-11-102015-12-29Us
AtenololTablet100 mg/1OralSandoz Inc1991-09-17Not applicableUs
AtenololTablet100 mg/1OralCadila Healthcare Limited2005-08-10Not applicableUs
AtenololTablet50 mg/1OralAphena Pharma Solutions Tennessee, Llc1993-03-30Not applicableUs
AtenololTablet50 mg/1OralAphena Pharma Solutions Tennessee, Llc1995-02-22Not applicableUs
AtenololTablet25 mg/1OralIngenus Pharmaceuticals, LLC2011-01-30Not applicableUs
AtenololTablet50 mg/1OralClinical Solutions Wholesale2007-12-04Not applicableUs
AtenololTablet50 mg/1OralA S Medication Solutions2005-10-08Not applicableUs
AtenololTablet50 mg/1OralSTAT Rx USA LLC2007-12-04Not applicableUs
AtenololTablet25 mg/1OralUnit Dose Services2004-11-16Not applicableUs
AtenololTablet25 mg/1OralMutual Pharmaceutical Company, Inc.1997-07-30Not applicableUs
AtenololTablet50 mg/1OralCardinal Health2011-06-20Not applicableUs
AtenololTablet50 mg/1OralDIRECT RX2015-01-01Not applicableUs
AtenololTablet100 mg/1OralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
AtenololTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-04-30Not applicableUs
AtenololTablet25 mg/1Oralbryant ranch prepack2007-12-04Not applicableUs
AtenololTablet25 mg/1OralLake Erie Medical DBA Quality Care Products LLC1992-05-01Not applicableUs
AtenololTablet50 mg/1OralContract Pharmacy Services Pa2011-01-30Not applicableUs
AtenololTablet25 mg/1OralREMEDYREPACK INC.2011-08-102016-11-05Us
AtenololTablet25 mg/1OralAvera Mc Kennan Hospital2015-03-20Not applicableUs
AtenololTablet25 mg/1OralMajor Pharmaceuticals1992-05-01Not applicableUs
AtenololTablet100 mg/1OralZydus Pharmaceuticals (USA) Inc.2005-10-08Not applicableUs
AtenololTablet25 mg/1OralAurolife Pharma LLC2011-06-20Not applicableUs
AtenololTablet50 mg/1OralNu Care Pharmaceuticals, Inc.2005-10-08Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2012-11-27Not applicableUs
AtenololTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC1991-09-17Not applicableUs
AtenololTablet50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet100 mg/1OralREMEDYREPACK INC.2015-06-10Not applicableUs
AtenololTablet100 mg/1OralA S Medication Solutions2005-10-08Not applicableUs
AtenololTablet25 mg/1OralAidarex Pharmaceuticals LLC2007-12-04Not applicableUs
AtenololTablet25 mg/1OralMylan Pharmaceuticals Inc.1999-06-17Not applicableUs
AtenololTablet50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.2007-12-04Not applicableUs
AtenololTablet25 mg/1OralRanbaxy Pharmaceuticals Inc.2007-12-04Not applicableUs
AtenololTablet25 mg/1OralBlenheim Pharmacal, Inc.2013-09-03Not applicableUs
AtenololTablet50 mg/1OralMed Vantx, Inc.2007-12-04Not applicableUs
AtenololTablet100 mg/1OralREMEDYREPACK INC.2011-06-062016-10-13Us
AtenololTablet25 mg/1OralPreferred Pharmaceuticals, Inc.2007-12-04Not applicableUs
AtenololTablet50 mg/1OralMed Health Pharma, LLC2011-01-20Not applicableUs
AtenololTablet50 mg/1OralA S Medication Solutions2005-10-08Not applicableUs
AtenololTablet25 mg/1OralMylan Institutional Inc.1999-06-16Not applicableUs
AtenololTablet25 mg/1OralApotheca Inc.2004-11-16Not applicableUs
AtenololTablet50 mg/1OralPack Pharmaceuticals LLC2010-06-10Not applicableUs
AtenololTablet25 mg/1OralPreferred Pharmaceuticals Inc.2016-08-22Not applicableUs
AtenololTablet25 mg/1OralH.J. Harkins Company, Inc.2007-12-04Not applicableUs
AtenololTablet100 mg/1OralPhysicians Total Care, Inc.1999-03-04Not applicableUs
AtenololTablet100 mg/1OralSt Marys Medical Park Pharmacy2013-07-10Not applicableUs
AtenololTablet100 mg/1OralSandoz Inc1991-09-17Not applicableUs
AtenololTablet25 mg/1OralTYA Pharmaceuticals2007-12-04Not applicableUs
AtenololTablet50 mg/1OralAv Kare, Inc.2013-06-17Not applicableUs
AtenololTablet100 mg/1OralRed Pharm Drug Inc.2007-12-04Not applicableUs
AtenololTablet25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-18Not applicableUs
AtenololTablet50 mg/1OralNorthstar Rx LLC2009-11-102015-12-29Us
AtenololTablet25 mg/1OralCardinal Health2011-06-20Not applicableUs
AtenololTablet50 mg/1OralAmerican Health Packaging2004-08-04Not applicableUs
AtenololTablet50 mg/1OralBlenheim Pharmacal, Inc.2010-01-07Not applicableUs
AtenololTablet25 mg/1OralAurobindo Pharma Limited2007-10-31Not applicableUs
AtenololTablet25 mg/1OralAphena Pharma Solutions Tennessee, Llc2004-11-16Not applicableUs
AtenololTablet100 mg/1OralAphena Pharma Solutions Tennessee, Llc1991-09-17Not applicableUs
AtenololTablet50 mg/1OralIngenus Pharmaceuticals, LLC2011-01-30Not applicableUs
AtenololTablet25 mg/1OralA S Medication Solutions2005-10-08Not applicableUs
AtenololTablet100 mg/1OralClinical Solutions Wholesale2007-12-04Not applicableUs
AtenololTablet100 mg/1OralA S Medication Solutions2005-10-08Not applicableUs
AtenololTablet25 mg/1OralRebel Distributors Corp.1995-07-19Not applicableUs
AtenololTablet25 mg/1OralDIRECT RX2014-01-01Not applicableUs
AtenololTablet50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet25 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
AtenololTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC1992-01-24Not applicableUs
AtenololTablet50 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
AtenololTablet25 mg/1OralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
AtenololTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1992-05-01Not applicableUs
AtenololTablet100 mg/1Oralbryant ranch prepack2007-12-04Not applicableUs
AtenololTablet100 mg/1OralRebel Distributors Corp2007-12-04Not applicableUs
AtenololTablet25 mg/1OralRed Pharm Drug Inc.2007-12-04Not applicableUs
AtenololTablet100 mg/1OralREMEDYREPACK INC.2011-09-292016-11-15Us
AtenololTablet25 mg/1OralMc Kesson Contract Packaging2011-10-03Not applicableUs
AtenololTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.1991-09-17Not applicableUs
AtenololTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2004-11-16Not applicableUs
AtenololTablet50 mg/1OralAurolife Pharma LLC2011-06-20Not applicableUs
AtenololTablet100 mg/1OralNu Care Pharmaceuticals, Inc.1995-02-17Not applicableUs
AtenololTablet25 mg/1OralProficient Rx LP2004-11-16Not applicableUs
AtenololTablet50 mg/1OralProficient Rx LP1995-02-22Not applicableUs
AtenololTablet50 mg/1OralAidarex Pharmaceuticals LLC2007-12-04Not applicableUs
AtenololTablet50 mg/1OralMylan Pharmaceuticals Inc.1992-01-24Not applicableUs
AtenololTablet25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet25 mg/1OralClinical Solutions Wholesale, Llc1992-05-01Not applicableUs
AtenololTablet50 mg/1OralRanbaxy Pharmaceuticals Inc.2007-12-04Not applicableUs
AtenololTablet25 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
AtenololTablet50 mg/1OralMed Vantx, Inc.2009-11-10Not applicableUs
AtenololTablet100 mg/1OralREMEDYREPACK INC.2011-07-132016-10-21Us
AtenololTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2007-12-04Not applicableUs
AtenololTablet100 mg/1OralMed Health Pharma, LLC2011-01-20Not applicableUs
AtenololTablet50 mg/1OralTeva Pharmaceuticals USA Inc1995-02-22Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2012-07-19Not applicableUs
AtenololTablet100 mg/1OralApotheca Inc.2005-10-08Not applicableUs
AtenololTablet100 mg/1OralPack Pharmaceuticals LLC2010-06-10Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2009-09-232016-11-01Us
AtenololTablet50 mg/1OralMutual Pharmaceutical Company, Inc.1993-03-30Not applicableUs
AtenololTablet25 mg/1OralPhysicians Total Care, Inc.1995-07-19Not applicableUs
AtenololTablet25 mg/1OralREMEDYREPACK INC.2015-12-10Not applicableUs
AtenololTablet25 mg/1OralSandoz Inc1992-05-01Not applicableUs
AtenololTablet25 mg/1OralCadila Healthcare Limited2005-08-10Not applicableUs
AtenololTablet100 mg/1OralAv Kare, Inc.2013-06-17Not applicableUs
AtenololTablet50 mg/1OralAphena Pharma Solutions Tennessee, Llc1991-09-17Not applicableUs
AtenololTablet50 mg/1OralUnit Dose Services2007-12-04Not applicableUs
AtenololTablet100 mg/1OralNorthstar Rx LLC2009-11-102015-12-29Us
AtenololTablet50 mg/1OralDIRECT RX2014-01-01Not applicableUs
AtenololTablet100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.2007-12-04Not applicableUs
AtenololTablet50 mg/1OralProficient Rx LP2007-12-04Not applicableUs
AtenololTablet25 mg/1OralBlenheim Pharmacal, Inc.2012-01-19Not applicableUs
AtenololTablet50 mg/1OralAurobindo Pharma Limited2007-10-31Not applicableUs
AtenololTablet25 mg/1OralREMEDYREPACK INC.2011-04-252016-10-13Us
AtenololTablet50 mg/1OralLegacy Pharmaceutical Packaging2007-12-04Not applicableUs
AtenololTablet100 mg/1OralIngenus Pharmaceuticals, LLC2011-01-30Not applicableUs
AtenololTablet100 mg/1OralUnit Dose Services2007-12-04Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2015-04-02Not applicableUs
AtenololTablet25 mg/1OralA S Medication Solutions2005-10-08Not applicableUs
AtenololTablet50 mg/1OralRebel Distributors Corp.1991-12-27Not applicableUs
AtenololTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1995-02-22Not applicableUs
AtenololTablet100 mg/1OralAurolife Pharma LLC2011-06-20Not applicableUs
AtenololTablet100 mg/1OralPreferred Pharmaceuticals Inc.2016-08-02Not applicableUs
AtenololTablet50 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
AtenololTablet50 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
AtenololTablet50 mg/1OralSt Marys Medical Park Pharmacy2007-12-04Not applicableUs
AtenololTablet25 mg/1OralSandoz Inc1992-05-01Not applicableUs
AtenololTablet25 mg/1OralReady Meds1992-05-01Not applicableUs
AtenololTablet50 mg/1OralRebel Distributors Corp2007-12-04Not applicableUs
AtenololTablet25 mg/1OralRed Pharm Drug Inc.2007-12-04Not applicableUs
AtenololTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-05-24Not applicableUs
AtenololTablet50 mg/1OralMc Kesson Contract Packaging2011-12-28Not applicableUs
AtenololTablet50 mg/1OralMylan Institutional Inc.1997-07-24Not applicableUs
AtenololTablet25 mg/1OralZydus Pharmaceuticals (USA) Inc.2005-10-08Not applicableUs
AtenololTablet100 mg/1OralNu Care Pharmaceuticals, Inc.2005-10-08Not applicableUs
AtenololTablet100 mg/1OralAidarex Pharmaceuticals LLC2007-12-04Not applicableUs
AtenololTablet100 mg/1OralMylan Pharmaceuticals Inc.1992-01-24Not applicableUs
AtenololTablet100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
AtenololTablet50 mg/1OralClinical Solutions Wholesale, Llc1991-09-17Not applicableUs
AtenololTablet100 mg/1OralRanbaxy Pharmaceuticals Inc.2007-12-04Not applicableUs
AtenololTablet100 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
AtenololTablet50 mg/1OralMed Vantx, Inc.1995-02-22Not applicableUs
AtenololTablet25 mg/1OralREMEDYREPACK INC.2011-07-082016-10-26Us
AtenololTablet100 mg/1OralPreferred Pharmaceuticals, Inc.2007-12-04Not applicableUs
AtenololTablet25 mg/1OralNorthwind Pharmaceuticals, LLC2014-06-24Not applicableUs
AtenololTablet100 mg/1OralTeva Pharmaceuticals USA Inc1995-02-17Not applicableUs
TenorminTablet100 mg/1OralNorthwind Pharmaceuticals2016-06-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MyocordIvax
NormitenTeva
Brand mixtures
NameLabellerIngredients
Apo-atenidoneApotex Inc
Atenolol and ChlorthalidoneMajor Pharmaceutical
Atenolol ScopolamineTps
Ntp-atenolol/chlorthalidoneTeva Canada Limited
TenoreticAstra Zeneca Pharmaceuticals Lp
Tenoretic 100/25mg TabAstrazeneca Canada Inc
Tenoretic 50/25mg TabAstrazeneca Canada Inc
Teva-atenolol/chlorthalidoneTeva Canada Limited
SaltsNot Available
Categories
UNII50VV3VW0TI
CAS number29122-68-7
WeightAverage: 266.3361
Monoisotopic: 266.16304258
Chemical FormulaC14H22N2O3
InChI KeyMETKIMKYRPQLGS-UHFFFAOYSA-N
InChI
InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
IUPAC Name
2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
SMILES
CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Pharmacology
IndicationFor the management of hypertention and long-term management of patients with angina pectoris
Structured Indications
PharmacodynamicsAtenolol, a competitive beta(1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it does not have intrinsic sympathomimetic properties or membrane-stabilizing activity. Atenolol is used alone or with chlorthalidone in the management of hypertension and edema.
Mechanism of actionLike metoprolol, atenolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension. Higher doses of atenolol also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknownNot AvailableHumanP07550 details
Related Articles
AbsorptionApproximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces.
Volume of distributionNot Available
Protein bindingPlasma protein binding is 6-16%
Metabolism

Hepatic (minimal)

Route of eliminationApproximately 50% of an oral dose is absorbed from the gastrointestinal tract, the remainder being excreted unchanged in the feces. Unlike propranolol or metoprolol, but like nadolol, atenolol undergoes little or no metabolism by the liver, and the absorbed portion is eliminated primarily by renal excretion.
Half life6-7 hours
ClearanceNot Available
ToxicityLD50=2000-3000 mg/kg(orally in mice). Symptoms of an atenolol overdose include a slow heart beat, shortness of breath, fainting, dizziness, weakness, confusion, nausea, and vomiting.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Atenolol Action PathwayDrug actionSMP00298
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableG > CBetter response to drug therapy22192668
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Atenolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Atenolol.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Atenolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Atenolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Atenolol.Approved
AcetaminophenThe serum concentration of Atenolol can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Atenolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideAtenolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Atenolol.Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Atenolol is combined with Acetylcholine.Approved
AcetyldigitoxinAtenolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Atenolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Atenolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Atenolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Atenolol.Experimental, Investigational
AlbendazoleThe serum concentration of Atenolol can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.Approved
AldosteroneThe serum concentration of Atenolol can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Atenolol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Atenolol can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Atenolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Atenolol is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Atenolol.Approved, Investigational
AlprenololAtenolol may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Atenolol can be increased when it is combined with Amantadine.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Atenolol.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Atenolol.Approved, Investigational
Ambroxol acefyllinateAtenolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineAtenolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Atenolol is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Atenolol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineAtenolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Atenolol.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Atenolol.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Atenolol.Approved, Illicit
AmodiaquineThe metabolism of Atenolol can be decreased when combined with Amodiaquine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Atenolol is combined with Amphotericin B.Approved, Investigational
AmpicillinThe bioavailability of Atenolol can be decreased when combined with Ampicillin.Approved, Vet Approved
AmprenavirThe serum concentration of Atenolol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Atenolol can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Atenolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Atenolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Atenolol.Approved
AnvirzelAtenolol may increase the bradycardic activities of Anvirzel.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Atenolol.Approved
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Atenolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Atenolol.Approved, Investigational
ArbutamineAtenolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Atenolol is combined with Arecoline.Experimental
ArformoterolAtenolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Atenolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Atenolol is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Atenolol.Approved, Investigational
AstemizoleThe serum concentration of Atenolol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Atenolol.Approved, Investigational
AtorvastatinThe serum concentration of Atenolol can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Atenolol.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Atenolol.Withdrawn
AzelastineThe serum concentration of Atenolol can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Atenolol is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Atenolol can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Atenolol.Approved, Investigational
BambuterolAtenolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Atenolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Atenolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Atenolol is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Atenolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Atenolol.Withdrawn
BenzocaineThe serum concentration of Atenolol can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Illicit
BepridilThe serum concentration of Atenolol can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantAtenolol may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Atenolol.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Atenolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Atenolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Atenolol.Investigational
BimatoprostAtenolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Atenolol can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Atenolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Atenolol.Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Atenolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Atenolol is combined with Bortezomib.Approved, Investigational
BosentanAtenolol may increase the hypotensive activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Atenolol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Atenolol.Approved
BretyliumBretylium may increase the bradycardic activities of Atenolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Atenolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Atenolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Atenolol.Investigational
BucindololAtenolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Atenolol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Atenolol.Approved, Investigational
BupranololAtenolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Atenolol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Atenolol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Atenolol.Approved
CabergolineAtenolol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Atenolol.Approved
CalfactantAtenolol may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Atenolol.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Atenolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Candesartan.Approved
CandoxatrilAtenolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Atenolol is combined with Carbachol.Approved
CarbamazepineThe serum concentration of Atenolol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Atenolol is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Atenolol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Atenolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Atenolol is combined with Carteolol.Approved
CarvedilolAtenolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Atenolol can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Atenolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Atenolol.Approved, Investigational
CeliprololAtenolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CeritinibAtenolol may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Atenolol.Withdrawn
CevimelineThe risk or severity of adverse effects can be increased when Atenolol is combined with Cevimeline.Approved
ChloroquineThe serum concentration of Atenolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Atenolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Atenolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Atenolol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Atenolol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Atenolol.Approved
CholesterolThe serum concentration of Atenolol can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Atenolol can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Atenolol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Atenolol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Atenolol.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Atenolol.Approved
ClarithromycinThe serum concentration of Atenolol can be increased when it is combined with Clarithromycin.Approved
ClenbuterolAtenolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Atenolol.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Atenolol is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Atenolol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Atenolol.Approved, Investigational
ClomipramineThe serum concentration of Atenolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Atenolol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Atenolol.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Atenolol can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Atenolol.Approved
CobicistatThe serum concentration of Atenolol can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Atenolol.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Atenolol.Approved
ColforsinThe serum concentration of Atenolol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Atenolol is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Atenolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Atenolol.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Atenolol.Approved
CryptenamineAtenolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Atenolol.Investigational
CyclophosphamideThe serum concentration of Atenolol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Atenolol can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideAtenolol may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Atenolol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atenolol.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Atenolol.Approved
DaclatasvirThe serum concentration of Atenolol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Atenolol can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Atenolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Atenolol can be increased when it is combined with Dapoxetine.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Atenolol.Approved, Investigational
DaunorubicinThe serum concentration of Atenolol can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Atenolol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Atenolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Atenolol.Approved
DeserpidineAtenolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Atenolol is combined with Desflurane.Approved
DesipramineThe serum concentration of Atenolol can be increased when it is combined with Desipramine.Approved
DeslanosideAtenolol may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe serum concentration of Atenolol can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Atenolol can be increased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Atenolol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Vet Approved
DextromethorphanThe serum concentration of Atenolol can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Atenolol.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Atenolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Atenolol.Vet Approved
DiclofenacThe serum concentration of Atenolol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Atenolol is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Atenolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Atenolol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Atenolol.Approved
DigoxinThe serum concentration of Atenolol can be decreased when it is combined with Digoxin.Approved
DihydralazineAtenolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Atenolol.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Atenolol is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Atenolol is combined with Dinutuximab.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Atenolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Atenolol.Approved
DobutamineAtenolol may decrease the bronchodilatory activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Atenolol.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Atenolol.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Atenolol.Approved
DorzolamideAtenolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinAtenolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Atenolol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Atenolol.Approved, Investigational
DoxorubicinThe serum concentration of Atenolol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Atenolol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneDronedarone may increase the bradycardic activities of Atenolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Atenolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
DuloxetineAtenolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Atenolol.Investigational
DyphyllineAtenolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Atenolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Atenolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Atenolol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Atenolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Atenolol.Approved
EfonidipineAtenolol may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Atenolol can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Atenolol.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Atenolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatAtenolol may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Atenolol can be increased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Atenolol is combined with EPIBATIDINE.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Atenolol.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Atenolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Atenolol is combined with Eplerenone.Approved
EpoprostenolAtenolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Eprosartan.Approved
Ergoloid mesylateAtenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineAtenolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Atenolol.Approved, Investigational
ErythromycinThe serum concentration of Atenolol can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Atenolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Atenolol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Atenolol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Atenolol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Atenolol can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Atenolol.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Atenolol.Approved
EtodolacEtodolac may decrease the antihypertensive activities of Atenolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Atenolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
EtoperidoneThe serum concentration of Atenolol can be increased when it is combined with Etoperidone.Approved
EtoposideThe serum concentration of Atenolol can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Atenolol.Approved, Investigational
EtravirineThe serum concentration of Atenolol can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Atenolol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Atenolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Atenolol.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Atenolol.Approved
FelodipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Atenolol.Approved
FenoldopamAtenolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Atenolol.Approved
FenoterolAtenolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylThe serum concentration of Atenolol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Atenolol.Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Atenolol.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Atenolol.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Atenolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Fimasartan.Approved
FingolimodAtenolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Atenolol.Approved, Withdrawn
FluconazoleThe serum concentration of Atenolol can be increased when it is combined with Fluconazole.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Atenolol.Vet Approved
FluoxetineThe serum concentration of Atenolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Atenolol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Atenolol can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Atenolol can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Atenolol.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Atenolol.Approved
FluvoxamineThe serum concentration of Atenolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolAtenolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Atenolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Atenolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Atenolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Atenolol.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Atenolol.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Atenolol.Approved
GenisteinThe serum concentration of Atenolol can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Atenolol.Approved, Nutraceutical
GlibornurideAtenolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideAtenolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAtenolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAtenolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneAtenolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideAtenolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideThe serum concentration of Atenolol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Atenolol can be increased when it is combined with Glycerol.Experimental
GlycopyrroniumThe serum concentration of Atenolol can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
Gramicidin DThe serum concentration of Atenolol can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Atenolol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Atenolol.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Atenolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Atenolol.Approved
GuanethidineAtenolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Atenolol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Atenolol is combined with Halothane.Approved, Vet Approved
HexamethoniumAtenolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Atenolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Atenolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Atenolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Atenolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Atenolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Atenolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Atenolol.Approved, Vet Approved
HydroflumethiazideAtenolol may increase the hypotensive activities of Hydroflumethiazide.Approved
HydroxychloroquineThe metabolism of Atenolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Atenolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Atenolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Atenolol.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Atenolol.Approved
IloprostIloprost may increase the hypotensive activities of Atenolol.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Atenolol.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Atenolol.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Atenolol.Approved
IndalpineThe serum concentration of Atenolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Atenolol is combined with Indapamide.Approved
IndenololAtenolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Atenolol can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Atenolol can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Atenolol.Withdrawn
IndoraminAtenolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkAtenolol may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypotensive activities of Atenolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Atenolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Atenolol.Approved, Investigational
IsavuconazoniumThe serum concentration of Atenolol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Atenolol.Approved
IsoetarineAtenolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Atenolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Atenolol.Approved, Withdrawn
IsoprenalineAtenolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Atenolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Atenolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Atenolol.Approved
ItraconazoleThe serum concentration of Atenolol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineAtenolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Atenolol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Atenolol.Approved, Vet Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Atenolol.Experimental
KetamineThe serum concentration of Atenolol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinAtenolol may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Atenolol.Approved
KetoconazoleThe serum concentration of Atenolol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Atenolol.Approved
LabetalolAtenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineAtenolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideAtenolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Atenolol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Atenolol.Approved, Investigational
LanreotideAtenolol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Atenolol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Atenolol can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostAtenolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Atenolol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Atenolol.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Atenolol.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Atenolol.Approved
LercanidipineAtenolol may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Atenolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Atenolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Atenolol is combined with Levobupivacaine.Approved
LevodopaAtenolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Atenolol.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Atenolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Atenolol is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Atenolol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Atenolol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Atenolol.Approved
LiothyronineThe serum concentration of Atenolol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Atenolol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Atenolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Atenolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
LomitapideThe serum concentration of Atenolol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Atenolol.Approved
LopinavirThe serum concentration of Atenolol can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Atenolol can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Atenolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Losartan.Approved
LovastatinThe serum concentration of Atenolol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Atenolol.Approved
LucinactantAtenolol may increase the bradycardic activities of Lucinactant.Approved
LumacaftorThe serum concentration of Atenolol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Atenolol.Approved, Investigational
MacitentanAtenolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Atenolol.Approved
MalathionMalathion may increase the bradycardic activities of Atenolol.Approved, Investigational
ManidipineAtenolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Atenolol is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Atenolol can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Atenolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Atenolol.Withdrawn
MebendazoleThe serum concentration of Atenolol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Atenolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Atenolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Atenolol.Approved
Megestrol acetateThe serum concentration of Atenolol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Atenolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Atenolol.Approved, Vet Approved
MeprobamateThe serum concentration of Atenolol can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may decrease the antihypertensive activities of Atenolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Atenolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Atenolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Atenolol is combined with Methacholine.Approved
MethadoneThe serum concentration of Atenolol can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Atenolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Atenolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Atenolol.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Atenolol.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Atenolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Atenolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Atenolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Atenolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Atenolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Atenolol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Atenolol.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Atenolol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Atenolol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Atenolol.Approved, Investigational
MetyrosineAtenolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe serum concentration of Atenolol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Atenolol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Atenolol can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineAtenolol may increase the bradycardic activities of Midodrine.Approved
MifepristoneThe serum concentration of Atenolol can be decreased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Atenolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Atenolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Atenolol is combined with Minoxidil.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Atenolol.Approved
MitomycinThe serum concentration of Atenolol can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Atenolol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Atenolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Atenolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Atenolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Atenolol.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Atenolol.Approved, Investigational
MoxonidineAtenolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atenolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Atenolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Atenolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Atenolol.Approved
NadololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Atenolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Atenolol.Approved
NaftopidilAtenolol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Atenolol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Atenolol.Approved, Vet Approved
NaltrexoneThe serum concentration of Atenolol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
NaringeninThe serum concentration of Atenolol can be increased when it is combined with Naringenin.Experimental
NCX 4016NCX 4016 may decrease the antihypertensive activities of Atenolol.Investigational
NebivololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Atenolol can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Atenolol can be decreased when it is combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Atenolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Atenolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Atenolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Atenolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Atenolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nicotine.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Atenolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Atenolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Atenolol.Approved
NiguldipineAtenolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Atenolol.Approved, Investigational
NilvadipineAtenolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Atenolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Atenolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Atenolol is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Atenolol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Atenolol can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Atenolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Atenolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Atenolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Atenolol.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Atenolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
NorethisteroneThe serum concentration of Atenolol can be decreased when it is combined with Norethisterone.Approved
ObinutuzumabAtenolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Atenolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Atenolol.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Atenolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Atenolol.Approved, Investigational
OlodaterolAtenolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Atenolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Atenolol.Approved
OmapatrilatAtenolol may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Atenolol.Approved
OmeprazoleThe serum concentration of Atenolol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineAtenolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Atenolol.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Atenolol.Approved
OuabainAtenolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Atenolol.Approved
OxprenololAtenolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Atenolol.Withdrawn
P-NitrophenolThe serum concentration of Atenolol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Atenolol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
Palmitic AcidThe serum concentration of Atenolol can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Atenolol.Approved, Investigational
PantoprazoleThe serum concentration of Atenolol can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Atenolol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Atenolol.Approved
PargylinePargyline may increase the hypotensive activities of Atenolol.Approved
ParoxetineThe serum concentration of Atenolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideAtenolol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Atenolol.Approved
PenbutololThe risk or severity of adverse effects can be increased when Atenolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Atenolol.Approved, Vet Approved
PentoliniumAtenolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Atenolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Atenolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Atenolol.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Atenolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Atenolol.Withdrawn
PhenobarbitalThe serum concentration of Atenolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineAtenolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Atenolol.Withdrawn
PhentolamineAtenolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Atenolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Atenolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Atenolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Atenolol.Approved, Investigational
PimozideThe serum concentration of Atenolol can be increased when it is combined with Pimozide.Approved
PinacidilAtenolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Atenolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Atenolol is combined with Pipamperone.Approved
PirbuterolAtenolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Atenolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Atenolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Atenolol.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Atenolol.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Atenolol.Withdrawn
Platelet Activating FactorThe serum concentration of Atenolol can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideAtenolol may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Atenolol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Atenolol.Approved
Poractant alfaAtenolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Atenolol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Atenolol is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Atenolol.Approved
PrazosinAtenolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Atenolol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Atenolol.Approved, Vet Approved
PrimaquineThe metabolism of Atenolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ProbenecidThe serum concentration of Atenolol can be increased when it is combined with Probenecid.Approved
ProcaterolAtenolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ProgesteroneThe serum concentration of Atenolol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Atenolol.Approved, Vet Approved
PromethazineThe serum concentration of Atenolol can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Atenolol.Approved
PropafenoneThe serum concentration of Atenolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Atenolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Atenolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Atenolol is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Atenolol can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Atenolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Atenolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Atenolol.Approved
QuercetinThe serum concentration of Atenolol can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Atenolol is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Atenolol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Atenolol can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Atenolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Atenolol.Approved
RanitidineThe serum concentration of Atenolol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Atenolol.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Atenolol.Approved
ReboxetineThe serum concentration of Atenolol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Atenolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Atenolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Atenolol.Approved
RescinnamineAtenolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Atenolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Atenolol.Experimental, Investigational
RifampicinThe serum concentration of Atenolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Atenolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Atenolol.Approved, Investigational
RilmenidineAtenolol may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Atenolol can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Atenolol is combined with Riociguat.Approved
RisperidoneAtenolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineAtenolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe serum concentration of Atenolol can be decreased when it is combined with Ritonavir.Approved, Investigational
RituximabAtenolol may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Atenolol.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Atenolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Atenolol.Investigational, Withdrawn
RolapitantThe serum concentration of Atenolol can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Atenolol.Approved, Investigational
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Atenolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Atenolol is combined with Rotigotine.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Atenolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Atenolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Atenolol.Withdrawn
SalbutamolAtenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Atenolol.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Atenolol.Approved, Vet Approved
SalmeterolAtenolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Atenolol.Approved
SaprisartanAtenolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Atenolol can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Atenolol can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Atenolol.Approved, Vet Approved
SelegilineThe serum concentration of Atenolol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Atenolol.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Atenolol.Approved, Investigational
SertralineThe serum concentration of Atenolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Atenolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Atenolol.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Atenolol.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Atenolol.Approved
SimvastatinThe serum concentration of Atenolol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Atenolol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Atenolol.Approved, Investigational
SitaxentanAtenolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Atenolol is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Atenolol.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Atenolol.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Atenolol is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Atenolol.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Atenolol.Experimental
SpiraprilAtenolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Atenolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Atenolol.Investigational
St. John's WortThe serum concentration of Atenolol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Atenolol can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Atenolol is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Atenolol can be decreased when it is combined with Streptozocin.Approved
SufentanilAtenolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Atenolol.Approved
SulfinpyrazoneThe serum concentration of Atenolol can be increased when it is combined with Sulfinpyrazone.Approved
SulindacSulindac may decrease the antihypertensive activities of Atenolol.Approved
SumatriptanThe serum concentration of Atenolol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Atenolol can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Atenolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Atenolol.Withdrawn
TacrolimusThe serum concentration of Atenolol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Atenolol.Approved, Investigational
TamoxifenThe serum concentration of Atenolol can be decreased when it is combined with Tamoxifen.Approved
TamsulosinAtenolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Atenolol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Atenolol.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Atenolol.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Atenolol is combined with Telmisartan.Approved, Investigational
TemocaprilAtenolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Atenolol.Approved
TenoxicamTenoxicam may decrease the antihypertensive activities of Atenolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Atenolol.Vet Approved
TerazosinAtenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbutalineAtenolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerfenadineThe serum concentration of Atenolol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Atenolol.Approved
TerlipressinAtenolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Atenolol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Atenolol can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Atenolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineAtenolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Atenolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Atenolol.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Atenolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Atenolol.Approved
TiboloneAtenolol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Atenolol.Approved
TicrynafenAtenolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Atenolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Atenolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Atenolol.Approved, Investigational
TolazamideAtenolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineAtenolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideAtenolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Atenolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Atenolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Atenolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Atenolol.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Atenolol.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Atenolol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Atenolol.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Atenolol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Atenolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Atenolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Atenolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Atenolol.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Atenolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Atenolol.Approved
TrazodoneThe serum concentration of Atenolol can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilAtenolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Atenolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Atenolol is combined with Triamterene.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Atenolol.Vet Approved
TrichlormethiazideAtenolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Atenolol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Atenolol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinAtenolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanAtenolol may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe serum concentration of Atenolol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Atenolol can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Atenolol.Approved
TroleandomycinThe serum concentration of Atenolol can be increased when it is combined with Troleandomycin.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Atenolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Atenolol.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Atenolol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Atenolol.Approved
UnoprostoneAtenolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Atenolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Atenolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Atenolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Atenolol is combined with Varenicline.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Atenolol.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Atenolol.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Atenolol.Approved
VerapamilThe risk or severity of adverse effects can be increased when Atenolol is combined with Verapamil.Approved
VilanterolAtenolol may decrease the bronchodilatory activities of Vilanterol.Approved
VinblastineThe serum concentration of Atenolol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Atenolol.Approved, Investigational
VincristineThe serum concentration of Atenolol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Atenolol can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineAtenolol may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Atenolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Atenolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Atenolol.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Atenolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Atenolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Atenolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Atenolol.Withdrawn
Food Interactions
  • Consult your doctor before taking large amounts of Vitamin K (Green leafy vegetables).
  • Take 30-60 minutes before meals, take at the same time each day.
References
Synthesis Reference

Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,663,607;
May 16, 1972; assigned to Imperial Chemical Industries Limited, England.
Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,836,671;
September 17, 1974; assigned to Imperial Chemical Industries Limited, England.

US3663607
General ReferencesNot Available
External Links
ATC CodesC07CB03C07FB03C07DB01C07BB03C07AB03C07CB53
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (112 KB)
MSDSDownload (72.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9831
Blood Brain Barrier-0.9505
Caco-2 permeable-0.7922
P-glycoprotein substrateSubstrate0.6773
P-glycoprotein inhibitor INon-inhibitor0.9446
P-glycoprotein inhibitor IINon-inhibitor0.9856
Renal organic cation transporterNon-inhibitor0.8959
CYP450 2C9 substrateNon-substrate0.8416
CYP450 2D6 substrateSubstrate0.5468
CYP450 3A4 substrateNon-substrate0.6826
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9163
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9379
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9537
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8691
BiodegradationNot ready biodegradable0.8969
Rat acute toxicity2.0932 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.996
hERG inhibition (predictor II)Non-inhibitor0.8861
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astrazeneca pharmaceuticals lp
  • Able laboratories inc
  • Apothecon sub bristol myers squibb co
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Dava pharmaceuticals inc
  • Genpharm pharmaceuticals inc
  • Ipca laboratories ltd
  • Ipr pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Northstar healthcare holdings ltd
  • Nostrum laboratories inc
  • Pliva inc
  • Sandoz inc
  • Scs pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Unique pharmaceutical laboratories
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Astrazeneca lp
Packagers
Dosage forms
FormRouteStrength
TabletOral50 mg/mg
TabletBuccal; Oral; Sublingual; Transmucosal
TabletOral25 mg
TabletOral
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral100 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Atenolol powder5.14USD g
Tenormin 100 mg tablet2.28USD tablet
Tenormin 25 mg tablet1.94USD tablet
Tenormin 50 mg tablet1.52USD tablet
Atenolol 100 mg tablet1.26USD tablet
Atenolol 50 mg tablet0.85USD tablet
Atenolol 25 mg tablet0.81USD tablet
Apo-Atenol 100 mg Tablet0.6USD tablet
Co Atenolol 100 mg Tablet0.6USD tablet
Mylan-Atenolol 100 mg Tablet0.6USD tablet
Novo-Atenol 100 mg Tablet0.6USD tablet
Phl-Atenolol 100 mg Tablet0.6USD tablet
Pms-Atenolol 100 mg Tablet0.6USD tablet
Ran-Atenolol 100 mg Tablet0.6USD tablet
Ratio-Atenolol 100 mg Tablet0.6USD tablet
Sandoz Atenolol 100 mg Tablet0.6USD tablet
Apo-Atenol 50 mg Tablet0.36USD tablet
Co Atenolol 50 mg Tablet0.36USD tablet
Mylan-Atenolol 50 mg Tablet0.36USD tablet
Novo-Atenol 50 mg Tablet0.36USD tablet
Phl-Atenolol 50 mg Tablet0.36USD tablet
Pms-Atenolol 50 mg Tablet0.36USD tablet
Ran-Atenolol 50 mg Tablet0.36USD tablet
Ratio-Atenolol 50 mg Tablet0.36USD tablet
Sandoz Atenolol 50 mg Tablet0.36USD tablet
Novo-Atenol 25 mg Tablet0.18USD tablet
Pms-Atenolol 25 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158-160Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,663,607; May 16, 1972; assigned to Imperial Chemical Industries Limited, England. Barrett, A.M., Carter, J., Hull, R., Le Count, D.J. and Squire, C.J.; U.S. Patent 3,836,671; September 17, 1974; assigned to Imperial Chemical Industries Limited, England.
water solubility1.33E+004 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.16HANSCH,C ET AL. (1995)
Caco2 permeability-6.44ADME Research, USCD
pKa9.6MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.429 mg/mLALOGPS
logP0.57ALOGPS
logP0.43ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area84.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity73.51 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-0uy0-0950000000-e882b8032954e2a624cfView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0076-4920000000-3c7f23b7695e5c4dcc4cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-0aos-9800000000-93a18f0e030605aa10aaView in MoNA
MSMass Spectrum (Electron Ionization)splash10-00e9-9000000000-6a38697da7945fdb1908View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetamides
Direct ParentPhenylacetamides
Alternative Parents
Substituents
  • Phenylacetamide
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • Primary carboxylic acid amide
  • Carboxamide group
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Schafer M, Frischkopf K, Taimor G, Piper HM, Schluter KD: Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol. 2000 Aug;279(2):C495-503. [PubMed:10913016 ]
  2. Brown RA, Ilg KJ, Chen AF, Ren J: Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption. Eur J Pharmacol. 2002 May 10;442(3):241-50. [PubMed:12065078 ]
  3. Horinouchi T, Morishima S, Tanaka T, Suzuki F, Tanaka Y, Koike K, Miwa S, Muramatsu I: Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol. Life Sci. 2007 Jul 12;81(5):399-404. Epub 2007 Jun 16. [PubMed:17628611 ]
  4. Alberti C, Monopoli A, Casati C, Forlani A, Sala C, Nador B, Ongini E, Morganti A: Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists. J Cardiovasc Pharmacol. 1997 Sep;30(3):320-4. [PubMed:9300315 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Nuttall SL, Routledge HC, Kendall MJ: A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179-86. [PubMed:12795776 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23